Welcome to our dedicated page for Amphastar Pharma news (Ticker: AMPH), a resource for investors and traders seeking the latest updates and insights on Amphastar Pharma stock.
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) is a biopharmaceutical company focused on technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin API products. The AMPH news feed on Stock Titan brings together the company’s press releases and market-moving updates so readers can follow how its product portfolio, licensing deals, and financial performance evolve over time.
News about Amphastar often centers on regulatory milestones and pipeline progress. The company has reported U.S. Food and Drug Administration approval of its ANDA for Iron Sucrose Injection, USP, a generic iron sucrose injection indicated for iron deficiency anemia in chronic kidney disease. It also issues updates on its ANDAs, biosimilar insulin candidate, and proprietary peptide and protein products, including licensed peptide assets targeting oncology and ophthalmology.
Another recurring theme in AMPH news is strategic licensing and research agreements. Amphastar has announced exclusive license agreements with Nanjing Anji Biotechnology Co., Ltd. and Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for proprietary peptide products and for AMP-110, a fully synthetic ACTH analog in early-phase human clinical development. The company also discloses contract research agreements for recombinant peptide research cell banks supporting its pipeline.
Investors can also track quarterly earnings releases, non-GAAP financial metrics, and share repurchase authorizations, as well as announcements about expanded manufacturing capacity and distribution partnerships, such as the exclusive distribution of BAQSIMI® in parts of the Greater China region. By following AMPH news, readers gain insight into Amphastar’s mix of complex generics, proprietary medicines, manufacturing footprint, and related-party agreements that shape its long-term business profile.
Amphastar Pharmaceuticals (NASDAQ:AMPH) announced its participation in the 2024 Wells Fargo Healthcare Conference. Key details include:
- CFO Bill Peters and EVP Tony Marrs will engage in a fireside chat
- The event is scheduled for Thursday, September 5, 2024, at 10:15 am EST
- Access to the presentation will be available on Amphastar's website at http://ir.amphastar.com
- The webcast will remain accessible for 30 days following the presentation
This participation underscores Amphastar's commitment to engaging with investors and sharing insights about the company's operations and future prospects in the pharmaceutical industry.
Amphastar Pharmaceuticals (NASDAQ:AMPH) reported strong financial results for Q2 2024. Key highlights include:
- Net revenues of $182.4 million, up 25% year-over-year
- GAAP net income of $37.9 million, or $0.73 per share
- Adjusted non-GAAP net income of $48.7 million, or $0.94 per share
The company's performance was driven by:
- BAQSIMI® sales of $30.9 million
- Epinephrine sales increase of 67% to $27.9 million
- Primatene MIST® sales growth of 38% to $22.9 million
Gross profit margin improved to 52.2% from 49.9% in Q2 2023. The company's pipeline includes 3 ANDAs, 3 biosimilars, and 4 generic products in development, targeting markets worth over $13 billion.
Amphastar Pharmaceuticals (NASDAQ:AMPH), a bio-pharmaceutical company specializing in technically challenging generic and proprietary injectable, inhalation, and intranasal products, has announced its second quarter 2024 earnings release and conference call. The company will disclose its financial results for the quarter ended June 30, 2024, after market close on Wednesday, August 7, 2024. A conference call to discuss these results is scheduled for 2:00 p.m. Pacific Time on the same day.
Investors can access the call by dialing 877-407-0989 (toll-free) or 201-389-0921 (international). The call will also be available via webcast on the company's website, with a replay accessible within 24 hours after the live call ends. Amphastar's products are primarily used in hospital or urgent care settings and are distributed through group purchasing organizations and drug wholesalers.
BetterInvesting Magazine has announced Amphastar Pharmaceuticals (NASDAQ: AMPH) as its 'Stock to Study' and Medtronic (NYSE: MDT) as its 'Undervalued Stock' for the September 2024 issue. The National Association of Investors Corp. (NAIC) encourages investors to focus on fundamentals and informed decision-making. The magazine's choices are informational and educational, not endorsements. A trial version of BetterInvesting's tools is available for non-members to analyze these stocks. The committee includes several CFA members who review the stocks, emphasizing investor education. Full details will be available in the magazine's September issue.
Amphastar Pharmaceuticals (NASDAQ: AMPH) has announced a $50 million increase to its share buyback program, effective from June 3, 2024. This initiative aims to counterbalance a dilution caused by the company's equity compensation programs. The repurchases will be made through various means, including open market and private block transactions. The company currently has three ANDAs filed with the FDA, targeting a market size of over $1.4 billion, and is developing three biosimilar products with a market size of over $7 billion and four generic products targeting over $3 billion. Amphastar's subsidiary in China, ANP, has multiple DMFs filed with the FDA and is developing additional DMFs. Amphastar primarily focuses on developing and marketing technically challenging generic and proprietary injectable, inhalation, and intranasal products, along with insulin API products.
Amphastar Pharmaceuticals announced that its CFO, Bill Peters, and EVP of Corporate Administration, Jacob Liawatidewi, will participate in a fireside chat at the Jefferies Global Healthcare Conference. This event is scheduled for June 6, 2024, at 12:30 pm EST. The discussion will be moderated by an analyst and focus on the company's strategic initiatives and financial outlook. Investors can access the webcast through Amphastar's website, which will be available for 30 days following the presentation.
Amphastar Pharmaceuticals has received FDA approval for its Abbreviated New Drug Application (ANDA) for Albuterol Sulfate Inhalation Aerosol. This product treats and prevents bronchospasm in patients aged four and older and is bioequivalent to Teva's ProAir® HFA. Amphastar plans to launch the product in Q3 2024. The U.S. market for branded and generic albuterol sulfate inhalation aerosols was approximately $1.7 billion as of March 2024. Amphastar also has three ANDAs, three biosimilar products, and four generic products in development, targeting markets worth over $11.4 billion. The approval underscores Amphastar’s manufacturing capabilities and commitment to developing complex inhalation products.
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) will have Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, join an Analyst-Moderated fireside chat at the Bank of America Health Care Conference on May 15th, 2024. The webcast will be accessible for 30 days on Amphastar's Pharmaceuticals website.
Amphastar Pharmaceuticals reported net revenues of $171.8 million for the three months ended March 31, 2024. The company achieved GAAP net income of $43.2 million and adjusted non-GAAP net income of $55.3 million. Notable highlights include BAQSIMI revenue growth of 22% over the first quarter of 2023. The company experienced positive sales increases in several key products like Glucagon, Epinephrine, and Primatene MIST ®. However, there were decreases in sales of Lidocaine, Enoxaparin, and Naloxone. The company's gross profit margin was 52.4% of net revenues, driven by factors like increased sales of higher-margin products. Amphastar's financial performance demonstrates a strong first quarter with promising growth potential.
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) will release its first quarter earnings for 2024 on May 8, 2024. The company focuses on developing, manufacturing, and selling generic and proprietary injectable, inhalation, and intranasal products. They also sell insulin API products primarily used in hospital settings. The conference call to discuss financial results will be held at 2:00 p.m. Pacific Time.